Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665155 | 0.79 | JAK2 (0.42) | DAOJAK2JAK1JAK3TYK2 | |
| SCHEMBL1662422 | 0.77 | DAO (0.48) | DAOAKR1B1LMNATP53LCK | |
| SCHEMBL1662357 | 0.76 | CDK2 (0.43) | DAOJAK2JAK1JAK3TYK2 | |
| SCHEMBL1662463 | 0.74 | JAK2 (0.41) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL12019137 | 0.73 | JAK2 (0.41) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL1662234 | 0.73 | JAK2 (0.42) | DAOJAK2JAK1JAK3TYK2 | |
| SCHEMBL1801291 | 0.68 | JAK1 (0.57) | JAK2JAK1JAK3TYK2 | |
| Hydrochloric Acid SCHEMBL4714401 | 0.67 | JAK1 (0.56) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL1803252 | 0.64 | JAK2 (0.59) | JAK2JAK1JAK3TYK2PLAT | |
| SCHEMBL6367286 | 0.64 | LMNA (0.40) | DAOAKR1B1NR3C1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | claimed |
| EP-2490693-A1 | PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2011049722-A1 | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | claimed |
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | CDK1, CDK5, TTBK1 | DAO 2121/4885JAK2 799/4885JAK1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.